Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Preventing the onset of diabetes with precision delivery of mesenchymal stem cells to the pancreas in a preclinical model.

Yarani R., Primavera R., Chetty S., Wang J., Kaur S., Haupt-Jorgensen M.

Animal Study on Type 1 Diabetes, Chronic Inflammation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41275292
PMCID
PMC12751359
DOI
10.1186/s13287-025-04807-3

Abstract (original English)

Background Mesenchymal stem cells (MSCs) represent a promising regenerative therapy associated with anti-inflammatory, anti-apoptotic, and pro-proliferative properties. Despite their significant potential for treating diabetes, the clinical application of MSCs has been hindered mainly due to the low number of intravenously (IV) injected cells that successfully reach the pancreas. Methods In this study, we assessed the protective potential of adipose tissue-derived MSCs (AD-MSCs) in preventing the development of diabetes using a streptozotocin (STZ)-induced diabetic rat model. AD-MSCs were administered 4 h after STZ either via conventional IV injection or through direct intra-arterial (IA) administration into the pancreas. Healthy (no STZ, no MSCs) and diabetic (STZ, no MSCs) control groups were also included. Results Our proof-of-concept data indicate that IA administration of AD-MSCs allowed rats to maintain glycemic control and respond appropriately to glucose challenges following STZ treatment, comparable to healthy controls. In contrast, rats receiving IV AD-MSCs developed hyperglycemia and failed to respond adequately to glucose challenges. In vitro studies demonstrated that AD-MSCs can enhance the viability and function (i.e. insulin secretion) of injured islets. Conclusion Local IA delivery of AD-MSCs into the pancreatic circulation effectively prevents the onset of diab

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem Cell TransplantationMesenchymal Stem CellsDiabetes Mellitus, ExperimentalRatsPancreasMaleRats, Sprague-DawleyAdipose TissueStreptozocin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research